Hope for rare eye disease: experimental gene therapy offered to control group

NCT ID NCT07307469

ENROLLING_BY_INVITATION Disease control Sponsor: Chigenovo Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated Apr 28, 2026 · Updated 16 times

Summary

This study provides the ZVS101e injection to 32 people with Bietti crystalline corneoretinal dystrophy who were previously in a control group. The goal is to offer treatment and check for side effects. Participants must have completed a 52-week follow-up in an earlier phase 3 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Henan Provincial People's Hospital

Zhengzhou, Henan, China
Peking University Third Hospital

Beijing, Beijing Municipality, China
Tianjin Medical University Eye Hospital

Tianjin, Tianjin Municipality, China
West China Hospital, Sichuan University

Chengdu, Sichuan, China
Zhongshan Ophthalmic Center, Sun Yat-sen University

Guangzhou, Guangdong, China

Conditions

Explore the condition pages connected to this study.

PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS)